Actively Recruiting
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Led by University Hospital, Strasbourg, France · Updated on 2026-01-15
100
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.
CONDITIONS
Official Title
A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Minor or adult subject
- Confirmed disseminated borreliosis by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi)
- Diagnosis occurred within 24 months of anti-CD20 monoclonal antibody treatment
- Received anti-CD20 treatment between January 1, 2010, and July 30, 2025
You will not qualify if you...
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Laboratoire de Bactériologie - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
P
Pierre BOYER, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here